Contemporary adjuvant polymethyl methacrylate cementation optimally limits recurrence in primary giant cell tumor of bone patients compared to bone grafting: a systematic review and meta-analysis

Table 1 The details of the six articles included in the current review and a meta-analysis

Study	Publication date	Follow-up	Patient no.	Surgical treatment groups	Recurrence rate	Recurrence ( n)
	(year)	(months)
Becker et al.[20]	2008	63	384	Total cohort
			78/384	wide resection	2.00%	1
			103/384	curettage (bone graft)	49.00%	56
			102/384	curettage + PMMA	22.00%	23
			74/384	curettage + PMMA + phenol	27.00%	20
			27/384	curettage + toxic(bone graft)	15.00%	4
Errani et al.[11]	2010	91	349	Total cohort
			149/349	wide resection	12.00%	18
			136/349	Curettage + burr + phenol	17.60%	24
			64/349	Curettage + burr + phenol + PMMA	12.50%	8
Kivioja et al.[15]	2008	60 months	294	Total cohort
			92/294	wide resection	12.00%	11
			47/294	curettage	51.00%	24
			147/294	curettage + PMMA	22.00%	32
Klenke et al.[2]	2010	108 months	118	Total cohort
			UN	wide resection	5.00%	unknown
			22/118	curettage + burr	32.00%	7
			32/118	curettage + burr + phenol	34.00%	11
			41/118	curettage + burr + phenol + PMMA	15.00%	6
Gaston et al.[12]	2011	76.5 months	330	Total cohort
			246/330	curettage	28.70%	67
			84/330	curettage + PMMA	14.30%	12
Jamshidi et al.[14]	2008	74 months	168	Total cohort
			40/168	curettage + bone	42.50%	17
			40/168	curettage + cement	30.00%	12
			46/168	curettage + burr + bone	21.70%	10
			42/168	curettage + burr + cement	16.70%	7
Harness et al. [22]	2004	72 months	31
			5/31	curettage + bone	40.00%	2
			26/31	curettage + PMMA	42.00%	11
Ozalp et al.[23]	2006	80 months	8	Total cohort
			6/8	curettage + bone	50.00%	3
			2/8	curettage + PMMA	50.00%	1
Sheth et al.[24]	1995	108 months	16	Total cohort
			9/16	curettage + bone	33.00%	3
			7/16	curettage + PMMA	28.50%	2

ISSN: 1477-7819